Literature DB >> 9191035

Lyme disease -- United States, 1996.

.   

Abstract

Lyme disease (LD) is caused by the tickborne spirochete Borrelia burgdorferi sensu lato and is the most common vectorborne disease in the United States. Surveillance for LD was initiated by CDC in 1982, and the Council of State and Territorial Epidemiologists designated it a nationally notifiable disease in January 1991. For surveillance purposes, LD is defined as the presence of an erythema migrans rash > or =5 cm in diameter or laboratory confirmation of infection with evidence of at least one manifestation of musculoskeletal, neurologic, or cardiovascular disease (1). This report summarizes the provisional number of cases of LD reported to CDC during 1996 and indicates that the number of cases reported to CDC was a record high.

Entities:  

Mesh:

Year:  1997        PMID: 9191035

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  32 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Patterns of Lyme disease diagnosis and treatment by family physicians in a southeastern state.

Authors:  John M Boltri; Robert B Hash; Robert L Vogel
Journal:  J Community Health       Date:  2002-12

3.  Methods for estimating gene frequencies and detecting selection in bacterial populations.

Authors:  B Rannala; W G Qiu; D E Dykhuizen
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

4.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

5.  Differential immune response to the variable surface loop antigen of P66 of Borrelia burgdorferi sensu lato species in geographically diverse populations of lyme borreliosis patients.

Authors:  Katharina Ornstein; Yngve Ostberg; Jonas Bunikis; Laila Noppa; Johan Berglund; Ragnar Norrby; Sven Bergström
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

6.  Decorin-binding protein of Borrelia burgdorferi is encoded within a two-gene operon and is protective in the murine model of Lyme borreliosis.

Authors:  K E Hagman; P Lahdenne; T G Popova; S F Porcella; D R Akins; J D Radolf; M V Norgard
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

7.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

8.  Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Authors:  D Schaarschmidt; R Oehme; P Kimmig; R D Hesch; S Englisch
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

9.  The cost effectiveness of vaccinating against Lyme disease.

Authors:  M I Meltzer; D T Dennis; K A Orloski
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

10.  Geographic risk for lyme disease and human granulocytic ehrlichiosis in southern New York state.

Authors:  T J Daniels; T M Boccia; S Varde; J Marcus; J Le; D J Bucher; R C Falco; I Schwartz
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.